基于PBPK模型预测儿童美罗培南、黏菌素和舒巴坦的组织暴露
本研究建立成人PBPK模型并外推至儿童,预测美罗培南、黏菌素和舒巴坦在多组织中的暴露,并与观察数据比较验证模型可靠性。模拟显示儿童给药方案在85-90%受试者中达到目标药效学指标,支持该联合方案用于儿童耐药鲍曼不动杆菌感染。
要点
- 成人及儿童血浆暴露模拟值与文献报道一致,模型可靠。
- 儿童给药方案:美罗培南30 mg/kg、舒巴坦40 mg/kg每日三次(3小时输注或持续输注),黏菌素5 mg/kg/日。
- 85-90%儿童受试者达到目标药效学指标,支持组织感染治疗。
核心结论
- PBPK模型支持儿童中美罗培南/黏菌素/舒巴坦联合给药用于鲍曼不动杆菌引起的血液、肺、皮肤和心脏组织感染。
研究设计与样本
- 建立成人PBPK模型并缩放至儿童,考虑肾脏和非肾脏清除,模拟血浆和组织药物暴露,与观察数据比较验证模型可靠性。
主要发现
- 美罗培南、黏菌素和舒巴坦的平均倍数误差范围分别为0.710-1.37、0.981-1.47和0.647-1.39。
- 模拟的血液、皮肤、肺和心脏暴露与报道的穿透率一致。
- 在2至<18岁虚拟儿童群体中,给予美罗培南30 mg/kg、舒巴坦40 mg/kg每日三次(3小时输注或持续输注)及黏菌素5 mg/kg/日,85-90%受试者达到目标药效学指标的解释性折点。
关键数值与推荐
- 儿童给药方案:美罗培南30 mg/kg、舒巴坦40 mg/kg每日三次(3小时输注或持续输注),黏菌素5 mg/kg/日。
- 85-90%的2至<18岁儿童受试者达到目标药效学指标。
临床怎么用
- 临床可参考该PBPK模型预测的儿童剂量方案,用于治疗鲍曼不动杆菌引起的血液、肺、皮肤和心脏组织感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three antibiotics are commonly used against major blood, skin, lung, and heart muscle infections. OBJECTIVE: The objective of this study was to predict drug disposition and extrapolate the efficacy in these tissues using a physiologically based pharmacokinetic modeling approach that linked drug exposures to their target pharmacodynamic indices associated with antimicrobial activities against A. baumannii. METHODS: An adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances. The model reliability was evaluated by comparing simulated plasma and tissue drug exposures to observed data. Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage. RESULTS: The modeled plasma drug exposures in adults and pediatric patients were consistent with reported literature data. The mean fold errors for meropenem, colistin, and sulbactam were in the range of 0.710-1.37, 0.981-1.47, and 0.647-1.39, respectively. Simulated exposures in the blood, skin, lung, and heart were consistent with reported penetration rates. In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity. CONCLUSIONS: The physiologically based pharmacokinetic modeling supports pediatric dosing regimens of meropenem/colistin/sulbactam in a co-administration setting against infections in the blood, lung, skin, and heart tissues due to A. baumannii.
引用
- Zhu S, Zhang J, Lv Z, et al. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2022. PMID: 35947360. doi:10.1007/s40262-022-01161-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。